We proceeded to assess the impact of Tcf-1 on the cytolytic activity of CD8+ T-cells engineered to express an anti-tumor TCR derived from tumor-infiltrating-lymphocytes: the 19,305-TCR, one which confers recognition of NY-ESO-1 presented in the context of HLA-A*02:01 [25]. The gene discussed is HLA-A; the disease is neoplasm.